ORCID

0009-0004-4995-841X (Vera), 0009-0001-6550-298X (Olexson), 0009-0000-3072-6732 (Ro), 0000-0002-6783-1904 (Enos)

Document Type

Abstract

Publication Date

2025

Publication Title

Journal of the American College of Cardiology

Volume

85

Issue

Suppl. 12

Pages

448

Abstract

Background: Psoriasis is an independent risk factor for major adverse cardiovascular events (MACE). We have previously shown that psoriasis patients with dyslipidemia have an increased incidence of MACE despite treatment with a biologic and a statin. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown to reduce MACE in patients with type 2 diabetes and obesity, comorbidities that commonly co-occur with psoriasis. However, the association between GLP-1RA and the incidence of MACE among patients with psoriasis remains unknown.

Methods: We conducted a retrospective cohort study from 2014-2024 using a large, multi-center, electronic health record network (TriNetX). Patients aged 18-90 who started GLP-1RA following their first psoriasis diagnosis and without a prior history of MACE were propensity score matched (PSM) 1:1 to GLP-1RA non-users. Covariates included demographics, social risk factors, comorbidities (e.g., obesity, type 2 diabetes, dyslipidemia), medications (e.g., biologics) and laboratory tests (e.g., cholesterol [total, LDL, HDL], triglycerides, blood pressure, C-reactive protein). The primary outcome was the incidence of composite MACE over a 10-year-period, evaluated using ORs and 95% confidence intervals.

Results: We identified 4791 psoriasis patients receiving GLP-1RA and 123,262 non-users, meeting criteria. Before matching, GLP-1RA users were older (53[40-66] vs 49[32-66]), more likely to be female (55% vs. 47%), and to have obesity (64% vs. 12%) diabetes (55% vs 7%), dyslipidemia (61% vs 20%) and social challenges 10% vs. 3% compared to control patients. PSM resulted in 4,378 patients in each cohort. MACE occured in 355 (8.11%) GLP-1RA users and 588 (13.43%) non-users (ORs 0.57; [0.50-0.65]) over a 10-year period.

Conclusion: GLP-1RA were associated with a lower incideence of MACE in patients with psoriasis compared to controls. These findings provide preliminary evidence of the potential benefit of GLP-1RA for MACE prevention among patients with psoriasis.

Rights

Copyright © 2025.

This is an Open Access Article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Original Publication Citation

Ormaza Vera, A., Osorio, M. F., Olexson, M., Choi, J., Ro, C., & Enos, C. (2025). Major adverse cardiovascular events are less frequent in psoriasis patients starting GLP-1RA compared to controls: An observational retrospective cohort study. Journal of the American College of Cardiology, 85(Suppl. 12), 448. https://www.jacc.org/doi/10.1016/S0735-1097%2825%2900932-5

Download

Share

COinS